Advertisement

Advertisement
Leukemia
Immunotherapy

Long-Term Follow-up of Children and Young Adults With B-Cell ALL Treated With CD19 CAR T-Cell Therapy

Autologous CD19 CAR T-cell therapy followed by allogeneic hematopoietic stem cell transplantation can produce prolonged disease control in pediatric patients with relapsed or refractory B-cell ALL...

Colorectal Cancer
Genomics/Genetics

Patients of Different Races With Early-Onset Colorectal Cancer Exhibit Distinct Genetic Features

Racial differences in genetic mutations were observed among patients with early-onset colorectal cancer...

American Cancer Society Names Karen E. Knudsen, MBA, PhD, as Its Next Chief Executive Officer

Karen E. Knudsen, MBA, PhD, will be the next CEO of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network, starting June 1, 2021...


Advertisement
Gastrointestinal Cancer

Anesthesiologist Volume and Adverse Short-Term Outcomes After Complex Surgery for Gastrointestinal Cancer

One study found that higher anesthesiologist volume was associated with reduced risk of short-term adverse postoperative outcomes in patients undergoing surgery for gastrointestinal cancer...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Gynecologic Cancers
COVID-19

Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research

Colorectal Cancer
Head and Neck Cancer

FDA Approves New Dosing Regimen for Cetuximab in Colorectal Cancer, Head and Neck Cancer

On April 6, the U.S. Food and Drug Administration (FDA) approved a new dosage regimen for cetuximab (Erbitux) of 500 mg/m2 as a 120-minute intravenous infusion every 2 weeks for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck. This...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Solid Tumors
Immunotherapy

Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care

Lung Cancer
Immunotherapy

First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLC

In the Chinese phase III RATIONALE 307 trial reported in JAMA Oncology, Wang et al found that tislelizumab plus chemotherapy significantly prolonged progression-free survival vs chemotherapy alone in the first-line treatment of patients with advanced squamous non–small cell lung cancer (NSCLC). As...

Breast Cancer
Immunotherapy

Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes

For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glenn Family Breast Cancer at the Winship Cancer Institute of Emory University, Atlanta. In the...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Gynecologic Cancers

Laura Chambers, DO, on Treating Epithelial Ovarian Cancer With Cisplatin and Paclitaxel During Surgery

Breast Cancer
COVID-19

Impact of COVID-19 Pandemic on Delivery of Breast Cancer Care in New York

In a single-institution retrospective study focused on a New York City location reported in JCO Oncology Practice, Satish et al found that more than 40% of patients with breast cancer not infected with COVID-19 had a delay or change in care delivery due to the pandemic. Study Details The study...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...